



**I-MAB**  
BIOPHARMA

## I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

April 5, 2024

ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the 23<sup>rd</sup> Annual Needham Virtual Healthcare Conference on April 11, 2024.

### 23<sup>rd</sup> Annual Needham Virtual Healthcare Conference

Presentation Time	Thursday, April 11 at 10:15 a.m. EST
Presenters	Raj Kannan, CEO; John Hayslip CMO
Webcast link	<a href="#">Here</a>
Meetings	One-on-one and small group meetings: April 11, 2024
Management Participants	Raj Kannan, CEO Joe Skelton, CFO John Hayslip, CMO Tyler Ehler, Senior Director, Investor Relations

The webcast will also be available under "Event Calendar" on I-Mab's IR website at <http://ir.i-mabbio.com/>

For more information, please contact your Needham representative.

### About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and in San Diego, California. For more information, please visit <http://www.i-mabbio.com> and follow us on LinkedIn and X.

### For more information, please contact:

Tyler Ehler  
Senior Director, Investor Relations  
[IR@imabbio.com](mailto:IR@imabbio.com)

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-23rd-annual-needham-virtual-healthcare-conference-302108935.html>

SOURCE I-Mab Biopharma